Rocket Pharmaceuticals withdraws review application to FDA for RP-L102

Rocket Pharmaceuticals (NASDAQ:RCKT) reported that it has voluntarily withdrawn its biologics marketing application to the U.S. FDA for mozafancogene autotemcel or RP-L102, an investigational gene therapy for the treatment of Fanconi Anemia. This decision follows the company’s previously announced corporate ...